Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,353,717
  • Shares Outstanding, K 60,320
  • Annual Sales, $ 1,619 M
  • Annual Income, $ 487,850 K
  • 36-Month Beta 0.94
  • Price/Sales 5.24
  • Price/Cash Flow 10.79
  • Price/Book 2.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 2.65
  • Number of Estimates 2
  • High Estimate 2.66
  • Low Estimate 2.63
  • Prior Year 2.58
  • Growth Rate Est. (year over year) +2.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
136.02 +2.20%
on 12/12/18
154.44 -9.99%
on 12/03/18
-3.79 (-2.65%)
since 11/16/18
3-Month
136.02 +2.20%
on 12/12/18
169.82 -18.14%
on 10/01/18
-22.92 (-14.15%)
since 09/18/18
52-Week
130.15 +6.81%
on 12/20/17
184.00 -24.45%
on 06/20/18
+4.92 (+3.67%)
since 12/18/17

Most Recent Stories

More News
Jazz (JAZZ) Increases Share Buyback Authorization by $400M

Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.

MLNT : 1.17 (-4.88%)
JAZZ : 139.00 (+0.37%)
HKMPF : 24.0000 (-9.08%)
BSTC : 61.65 (-3.43%)
Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million

Jazz Pharmaceuticals plc today announced that its Board of Directors has authorized a $400 million increase in the company's share repurchase program, which the company intends to use over time based...

JAZZ : 139.00 (+0.37%)
Why Is Jazz (JAZZ) Up 3% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ : 139.00 (+0.37%)
Report: Exploring Fundamental Drivers Behind Jazz Pharmaceuticals, 58, Encore Capital Group, Churchill Downs, Addus HomeCare, and Huntington Ingalls Industries -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Jazz Pharmaceuticals PLC...

CHDN : 258.11 (+1.51%)
JAZZ : 139.00 (+0.37%)
WUBA : 57.54 (-1.66%)
ECPG : 22.94 (+2.18%)
HII : 197.83 (+0.24%)
ADUS : 67.00 (-2.00%)
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial evaluating the efficacy and safety of JZP-258 for the treatment of idiopathic...

JAZZ : 139.00 (+0.37%)
Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that nine abstracts, including two oral presentations, relating to the company's hematology/oncology portfolio were accepted for the 60th American...

JAZZ : 139.00 (+0.37%)
Moving Average Crossover Alert: Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals plc (JAZZ) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

JAZZ : 139.00 (+0.37%)
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea

DUBLIN, Nov. 9, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, a selective...

JAZZ : 139.00 (+0.37%)
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View

Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.

JAZZ : 139.00 (+0.37%)
VRTX : 163.34 (-1.70%)
AMRX : 16.15 (-0.37%)
ALKS : 32.29 (-2.00%)
National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending Vyxeos® 44 mg/100...

JAZZ : 139.00 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade JAZZ with:

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 143.54
1st Resistance Point 141.02
Last Price 139.00
1st Support Level 137.16
2nd Support Level 135.82

See More

52-Week High 184.00
Fibonacci 61.8% 163.43
Fibonacci 50% 157.07
Fibonacci 38.2% 150.72
Last Price 139.00
52-Week Low 130.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar